Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q4 FY26 Earnings Presentation
11 slides from Natco Pharma's earnings presentation, May 29, 2026
Slide 1: Exchange filing cover letter for FY 25-26 Investor Presentation
May 29, 2025 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - FY 25-26 Inve
Slide 2: NATCO Pharma Limited Earnings Presentation Q4FY26 & FY26
NATCO Pharma Limited Earnings Presentation Q4FY26 & FY26
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q4FY26 - Key Business & Consolidated Financial Highlights
Q4FY26 - Key Business & Consolidated Financial Highlights Total Revenue for Q4FY26 stood at INR 8,169 Mn | Pharma Export Formulations at INR 5,396 Mn | Domestic Formulations Revenue at 1,087 Mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 2,054 Mn and EBITDA Margin at 25.1
Slide 5: FY26 - Key Business & Consolidated Financial Highlights
FY26 - Key Business & Consolidated Financial Highlights Total Revenue for FY26 stood at INR 43,759 Mn | Pharma Export Formulations at INR 32,345 Mn | Domestic Formulations Revenue at 4,409 Mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 17,341 Mn and EBITDA Margin at 39.6%
Slide 6: Q4 FY26 & FY26 – Segmental Performance
Q4 FY26 & FY26 – Segmental Performance Revenue Breakup (INR Mn) Q4FY26 Q4FY25 Q3FY26 FY26 FY25 Revenue Breakup (%) – Q4FY26 10.1 7.8 API Revenue 639 464 643 2,347 2,018 2.8 Pharmaceutical Formulation 17 Formulation – Exports (incl profit share, license 66 5,396 10,525 4,214 32,345 37,597 income, exp
Slide 7: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q4FY26 Q4FY25 Q3FY26 FY26 FY25 Total Revenue 8,169 12,873 7,054 43,759 47,840 Total Expenses (before finance cost and depreciation) 6,115 6,729 4,886 26,418 22,335 Earnings before interest, tax, depreciation and amortization (EBIT
Slide 8: Key Product Pipeline - USA
Key Product Pipeline - USA Para IVs in the pipeline, with 28 over 20 FTFs (incl. Sole and 17 Approved (either tentative or fully) Shared) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeutic segment/ Therapeutic segment/ Brand Molecule Brand
Slide 9: Our NCE | Cell & Gene Therapy Investments
Our NCE | Cell & Gene Therapy Investments 1 eGenesis 3 Cellogen Therapeutics Invested US$ 8 million in a biotechnology company Invested US$ 2 million focused on advanced cellular focused on xenotransplantation, by developing safe and engineering methods and gene-therapy-based effective human compati
Slide 10: Earnings Call Details – Q4 FY26 & FY26
Earnings Call Details – Q4 FY26 & FY26 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer, Mr. Amit Parekh, Chief Financial Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health
Slide 11: Thank You
Thank You Contact: Rajeev Menon – Investor Relations r.menon@natcopharma.co.in / ir@natcopharma.co.in 040-23546208/ Ext: 323 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma NATCO Pharma Limited – Earnings Presentation Q4 FY26 & FY26